Lilly Commits $90 Million for Global Health ProjectBy
Eli Lilly and Company has announced a new global health project with a plan to reach 30 million people in resource-limited settings annually by 2030. Known as Lilly 30×30, the plan includes a five-year, $90 million investment in the Lilly Global Health Partnership, which will improve access to treatment for diabetes, cancer, and tuberculosis (TB). One-half of the $90 million commitment will come from the Eli Lilly and Company Foundation (Foundation) and the other half will come from company funds.
John C. Lechleiter, PhD, Lilly chairman, president, and chief executive officer said in a company statement: “Over the last two decades, we have made tremendous progress in expanding access to quality care in poorer communities, but we can and must do more. Lilly 30×30 is a company-wide mandate to achieve a six-fold increase in the number of people we reach annually, outside of our traditional business.”
Lechleiter continued, “We will engage the entire Lilly organization to ensure that our aspirational goals are met. The investments announced today will help millions more benefit from Lilly’s life-saving work and accelerate our contributions toward the UN Sustainable Development Goals.”
Working with partners, the Lilly Global Health Partnership will help people living in communities with limited resources in Brazil, China, India, Kenya, Mexico, Russia, South Africa, and the US. Lilly will advance its existing global health work in many of these communities while identifying new opportunities for partnership. Consistent with the company’s evidence-based approach, the Lilly Global Health Partnership will research new models of care, report findings, and advocate for the scale-up of the most effective solutions to help more people.
The Lilly Global Health Partnership includes a new $15 million commitment to the Infectious Disease Research Institute (IDRI). This new commitment extends an eight-year collaboration to accelerate early-stage drug discovery and preclinical development for potential new TB medicines.
Source: Eli Lilly and Company